Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma.
Future Oncol
; 14(3): 255-266, 2018 Feb.
Article
en En
| MEDLINE
| ID: mdl-29219612
ABSTRACT
AIM:
To assess the association between tumor response and health-related quality of life (HRQoL) in patients with metastatic Merkel cell carcinoma treated with the anti-PD-L1 avelumab. MATERIALS &METHODS:
Phase II single-arm trial (NCT02155647) data of 88 patients were analyzed. Correlations between percentage reduction in tumor size and change from baseline in Functional Assessment of Cancer Therapy - General (FACT-G), FACT - Melanoma (FACT-M) and EuroQol-5 Dimension scores were calculated. HRQoL and utility by tumor response (per the Response Evaluation Criteria In Solid Tumors version 1.1) was estimated.RESULTS:
Tumor shrinkage correlated positively with patients' change from baseline in the FACT-M total (0.364 [95% CI 0.050-0.607]) and subscale scores. Differences in HRQoL and utility between nonprogressive disease and progressive disease were clinically relevant.CONCLUSION:
In patients with metastatic Merkel cell carcinoma, nonprogression during treatment with avelumab correlated with gains in HRQoL.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Calidad de Vida
/
Carcinoma de Células de Merkel
/
Terapia Molecular Dirigida
/
Antineoplásicos Inmunológicos
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos